Is Lakefront Biotherapeutics N.V. (LKFT) a Buy, Sell, or Hold?
NASDAQ : LKFT
Lakefront Biotherapeutics N.V.
$28.15 USD
$0.02 (0.07%)
- Volume
- 124.84K
- Average Volume
- 173.63K
- Market Capitalization
- $1.86B
- P/E Ratio
- 3.33
- Dividend Yield
- 0.00%
- Price Target
- $30.00
- Year High
- $37.78
- Year Low
- $26.42
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $30.48
Company Overview
NASDAQ
Henry O. Gosebruch
Biotechnology
Healthcare
LKFT
452
BE
USD
Liquidity Metrics
0.00
30.48
30.30
0.67
0.00
Sales & Valuation
$1.11B
1.56
0.50
-5.25
-4.71
Profitability
$4.87
$320.88M
46.83%
45.14%
16.88%
14.49%
P/E Metrics
3.33
-0.01
-0.01
Analyst Price Target & Rating
$30.00
$30.00
$30.00
4/5
1 Analysts
-6.17%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
$1.57B
1.51
3.30
30.48
16.88%
18.22%
29.96%
-19.02%
$90.80
-1351 days
Company Executives
| Name | Title |
|---|---|
| Jason Treese | Global Head of Quality |
| Fred W. Blakeslee | Executive VP & General Counsel |
| Jeevan Shetty | Head of Clinical Development Oncology |
| John W. Mellors | Head of Cell & Antibody Therapy Discovery |
| Henry Gosebruch | CEO & Executive Director |
| Annelies Missotten | Executive Officer |
| Ellen Van Der Aar | Head of Development |
| Tania Philipp | Chief Human Resources Officer |
| Ruiz Astigarraga | Head of Manufacturing Cell Therapy |
| Aaron L. Cox | Chief Financial Officer |
| Glenn Schulman D. | Head of Investor Relations |
| Marieke Vermeersch | Head of Corporate Communication |
Poll Results
No votes yet today — be the first to share your view!
About Lakefront Biotherapeutics N.V. (NASDAQ:LKFT) Stock
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium. ...
2026-07-28 16:01:00
Mechelen, Belgium; July 28, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between July 20, 2026 and July 24, 2026, it has repurchased 95,670 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 20/07/2026 XAMS 17,936 26.05 467,150.29 25.62 26.40 20/07/2026 CEUX 3,372 25.79 86,979.73 25.70 26.14 20/07/2026 AQEU 101 25.72 2,597.72 25.72 25.72 20/07/2026 TQEX 74 26.22 1,940.28 26.22 26.22 21/07/2026 XAMS 14,022 25.59 358,820.18 25.34 25.80 21/07/2026 CEUX 1,506 25.57 38,513.84 25.52 25.66 21/07/2026 AQEU 227 25.53 5,795.01 25.52 25.70 21/07/2026 TQEX 506 25.56 12,931.79 25.52 25.58 22/07/2026 XAMS 15,385 25.61 394,028.31 25.48 25.72 22/07/2026 CEUX 1,245 25.63 31,907.36 25.62 25.68 22/07/2026 AQEU 490 25.62 12,553.80 25.62 25.62 22/07/2026 TQEX 185 25.68 4,750.13 25.62 25.68 23/07/2026 XAMS 17,120 25.13 430,292.37 24.70 25.62 23/07/2026 CEUX 2,945 24.81 73,071.34 24.74 25.12 23/07/2026 AQEU 61 24.78 1,511.58 24.78 24.78 23/07/2026 TQEX 61 24.78 1,511.58 24.78 24.78 24/07/2026 XAMS 17,407 24.81 431,940.78 24.56 25.00 24/07/2026 CEUX 1,729 24.77 42,830.62 24.60 24.98 24/07/2026 AQEU 1,159 24.91 28,875.91 24.62 24.96 24/07/2026 TQEX 139 24.75 3,439.68 24.62 24.92 Total 95,670 25.41 2,431,442.30 24.56 26.40 As of market close on July 24, 2026, Lakefront holds 606,719 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
2026-07-28 16:01:00
Mechelen, Belgium; July 28, 2026, 22. 01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext and NASDAQ: LKFT) ("Lakefront") announces that between July 20, 2026 and July 24, 2026, it has repurchased 95,670 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: As of market close on July 24, 2026, Lakefront holds 606,719 of its own ordinary shares.
2026-07-28 16:01:00
Mechelen, België; 28 juli 2026, 22. 01 CET; gereglementeerde informatie In het kader van het op 9 juni 2026 aangekondigde inkoopprogramma maakt Lakefront Biotherapeutics NV (Euronext and NASDAQ: LKFT) ("Lakefront") bekend dat het tussen 20 juli 2026 en 24 juli 2026 via een discretionair mandaat aan een onafhankelijke financiële tussenpartij 95. 670 Lakefront-aandelen heeft ingekocht, als volgt: Bij het sluiten van de beurs op 24 juli 2026 hield Lakefront 606. 719 van zijn eigen gewone aandelen aan. Over Lakefront BiotherapeuticsLakefront Biotherapeutics (voorheen bekend als Galapagos) is een biotechnologiebedrijf dat zich richt op de uitbouw van een gedifferentieerde geneesmiddelenpijplijn voor patiënten met ernstige aandoeningen waarvoor nog een grote onvervulde medische nood bestaat.
2026-07-21 16:01:00
Mechelen, Belgium; July 21, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between July 13, 2026 and July 17, 2026 it has repurchased 98,648 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 13/07/2026 XAMS 20,583 26.38 543,006.30 26.12 26.56 13/07/2026 CEUX 1,842 26.39 48,613.33 26.30 26.54 13/07/2026 AQEU 238 26.41 6,286.13 26.34 26.54 13/07/2026 TQEX 532 26.41 14,049.69 26.34 26.46 14/07/2026 XAMS 19,825 26.01 515,672.04 25.74 26.34 14/07/2026 CEUX 2,289 25.99 59,486.07 25.84 26.20 14/07/2026 AQEU 170 25.86 4,396.20 25.86 25.86 14/07/2026 TQEX 987 26.08 25,736.81 26.06 26.18 15/07/2026 XAMS 15,770 25.75 406,156.35 25.62 25.96 15/07/2026 CEUX 422 25.73 10,857.47 25.62 25.78 15/07/2026 AQEU 476 25.72 12,244.15 25.62 25.76 15/07/2026 TQEX 906 25.79 23,368.73 25.62 25.80 16/07/2026 XAMS 16,485 25.93 427,428.03 25.76 26.10 16/07/2026 CEUX 1,137 25.93 29,483.89 25.88 26.00 16/07/2026 AQEU 68 25.92 1,762.56 25.92 25.92 16/07/2026 TQEX 528 25.94 13,695.21 25.92 25.94 17/07/2026 XAMS 14,972 25.77 385,768.55 25.60 26.04 17/07/2026 CEUX 1,368 25.83 35,337.22 25.70 26.02 17/07/2026 TQEX 50 25.70 1,285.00 25.70 25.70 Total 98,648 26.00 2,564,633.73 25.60 26.56 As of market close on July 17, 2026, Lakefront holds 511,049 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
2026-07-14 16:01:00
Mechelen, Belgium; 14 July 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 108,645 Lakefront shares between 06 July 2026 and 10 July 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 06/07/2026 XAMS 20,236 26.54 536,964.28 26.20 26.90 06/07/2026 CEUX 2,499 26.69 66,710.06 26.32 26.90 06/07/2026 TQEX 355 26.72 9,486.20 26.52 26.90 06/07/2026 AQEU 319 26.58 8,477.65 26.52 26.88 07/07/2026 XAMS 16,553 26.65 441,104.34 26.40 26.86 07/07/2026 CEUX 1,578 26.55 41,894.01 26.44 26.76 07/07/2026 TQEX 821 26.64 21,872.92 26.60 26.70 07/07/2026 AQEU 49 26.60 1,303.40 26.60 26.60 08/07/2026 XAMS 17,502 26.84 469,793.93 26.66 27.00 08/07/2026 CEUX 4,339 26.89 116,674.84 26.74 26.96 08/07/2026 TQEX 1,157 26.87 31,086.62 26.76 26.94 08/07/2026 AQEU 416 26.86 11,172.18 26.80 26.94 09/07/2026 XAMS 16,919 26.77 452,892.87 26.56 26.90 09/07/2026 CEUX 2,717 26.79 72,781.09 26.70 26.96 09/07/2026 TQEX 23 26.76 615.48 26.76 26.76 09/07/2026 AQEU 400 26.77 10,707.04 26.76 26.78 10/07/2026 XAMS 19,764 26.52 524,208.48 26.14 26.90 10/07/2026 CEUX 2,009 26.66 53,568.98 26.26 26.92 10/07/2026 TQEX 692 26.65 18,443.74 26.24 26.78 10/07/2026 AQEU 297 26.82 7,964.53 26.26 26.92 Total 108,645 26.67 2,897,722.65 26.14 27.00 As of market close on 10 July 2026, Lakefront holds 412,401 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.
2026-07-13 16:01:00
Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext and NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research and Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.
2026-07-13 16:01:00
Mechelen, België; 13 juli 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext and NASDAQ: LKFT) heeft vandaag bekendgemaakt dat dr. Paulo Fontoura, na zijn benoeming tot Executive Vice President en Global Head of Research and Development Pharma bij Sanofi SA, zijn mandaat als lid van de Raad van Bestuur heeft neergelegd. "Ik wil Paulo feliciteren met deze belangrijke benoeming en hem oprecht bedanken voor zijn inzichten en begeleiding tijdens zijn ambtstermijn in onze Raad van Bestuur.
2026-07-13 16:01:00
Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research & Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.
Frequently Asked Questions
-
What is the current Lakefront Biotherapeutics N.V. (LKFT) stock price?
-
Lakefront Biotherapeutics N.V.(NASDAQ:LKFT) stock price is $28.15 in the last trading session. During the trading session, LKFT stock reached the peak price of $37.78 while $26.42 was the lowest point it dropped to. The percentage change in LKFT stock occurred in the recent session was 0.07% while the dollar amount for the price change in LKFT stock was $0.02.
-
LKFT's industry and sector of operation?
-
The NASDAQ listed LKFT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of LKFT?
-
Jason Treese | Global Head of Quality
Fred W. Blakeslee | Executive VP & General Counsel
Jeevan Shetty | Head of Clinical Development Oncology
John W. Mellors | Head of Cell & Antibody Therapy Discovery
Henry Gosebruch | CEO & Executive Director -
How many employees does LKFT have?
-
Number of LKFT employees currently stands at 452. LKFT operates from SchaliEnhoevedreef 20 T, Mechelen, None 2800, BE.
-
Link for LKFT official website?
-
Official Website of LKFT is: https://www.galapagos.com
-
How do I contact LKFT?
-
LKFT could be contacted at phone #32 1 534 29 00 and can also be accessed through its website. LKFT operates from SchaliEnhoevedreef 20 T, Mechelen, None 2800, BE.
-
How many shares of LKFT are traded daily?
-
The average number of LKFT shares traded daily for last 3 months was 173.63K.
-
What is the market cap of LKFT currently?
-
The market value of LKFT currently stands at $1.86B with its latest stock price at $28.15